Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer
- 1 November 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (21), 10592-10599
- https://doi.org/10.1158/0008-5472.can-07-1917
Abstract
Androgen receptor (AR) activity is critical for prostate cancer progression. Overexpression of several AR-associated coactivators has been shown to be essential for AR activation during disease progression. The stimuli and signaling pathways leading to overexpression of these coregulators, however, remain largely elusive. Here, we investigated whether androgen signaling, which demarcates critical transitions during prostate cancer disease progression, can affect coregulator expression. We found that expression of four and a half LIM domain protein-2 (FHL2), a key AR coactivator that is overexpressed in prostate cancer and associates with a poor prognosis, is induced strongly by androgens. Androgen induction of this coactivator established a feed-forward mechanism that robustly activated the AR. Stimulation of FHL2 after androgen exposure was time- and dose-dependent and relied on the presence of a functional AR. Androgen induction of FHL2 depended on active transcription of the FHL2 gene, mediated by action of serum response factor (SRF) on its proximal promoter. Loss of SRF, a transcription factor that preferentially regulates the expression of genes involved in mitogenic response and cytoskeletal organization, hampered prostate cancer cell proliferation. These results suggest a novel indirect mechanism of androgen action on FHL2 expression and provide evidence that SRF is an important determinant of AR action in prostate cancer cells. [Cancer Res 2007;67(21):10592–9]Other Versions
This publication has 40 references indexed in Scilit:
- Physical and Functional Interactions between the Prostate Suppressor Homeoprotein NKX3.1 and Serum Response FactorJournal of Molecular Biology, 2006
- Going nuclear in metabolic and cardiovascular diseaseJCI Insight, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- p300 Regulates Androgen Receptor–Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6Cancer Research, 2005
- Predicting the effect of transcription therapy in hematologic malignanciesLeukemia, 2005
- Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid?Cancer Biology & Therapy, 2005
- Interaction and Functional Cooperation between the LIM Protein FHL2, CBP/p300, and β-CateninMolecular and Cellular Biology, 2004
- The LIM domain: from the cytoskeleton to the nucleusNature Reviews Molecular Cell Biology, 2004
- Coregulator-Related DiseasesInternal Medicine, 2004
- The Smooth Muscle γ-Actin Gene Promoter Is a Molecular Target for the Mouse bagpipe Homologue, mNkx3-1, and Serum Response FactorPublished by Elsevier BV ,2000